TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
TScan Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.21−0.02 (-9.00%)
Close on Oct 19, 2026
- Market cap
- $27.32M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.2698 (−91.52%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
TScan Therapeutics, Inc. grew revenue 2.2% to $7.11M over the twelve months to Jun 30, 2026. Free cash flow was -$118.44M.
Revenue
$7.11M
+2.2% vs. a year earlier
Operating income
-$120.54M
TTM Q2 2026
Free cash flow
-$118.44M
TTM Q2 2026
EPS, diluted
-$0.91
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $27.32M
- P/E ratio
- –
- Price to sales
- 3.84
- Price to book
- 0.40
- Dividend yield
- –
- Free cash flow yield
- -433.60%
Fundamentals
- Revenue
- $7.11M
- Net income
- -$117.71M
- EPS, diluted
- -$0.91
- Free cash flow
- -$118.44M
- Book value per share
- $0.53
- Diluted shares
- 130M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$7.11M+2.2% YoY
Operating income
-$120.54M
Net income
-$117.71M
EPS, diluted
-$0.91
Free cash flow
-$118.44M
Reported periodTrailing twelve months